Comparison was made of the pharmacokinetics of the radioisotope 65 Zinc ( 65 Zn) in blood, plasma, and whole body of adult channel cat5sh (Ictalurus punctatus) following intravascular (iv) administration. A two-compartment model described the pharmacokinetics of 65 Zn in plasma and blood during the 5rst 40 days following iv administration, but was unable to describe the longterm disposition of 65 Zn. Whole-body counting revealed that approximately half of the 65 Zn dose was sequestered in a slowly exchangeable pool with a half-life of 1.5 years. Greater than 99% of the circulating 65 Zn was bound to plasma proteins, whereas there was less than 1% binding to red blood cells. Synthesis of the results for channel cat5sh and existing data in other species indicates three phases in the pharmacokinetics of zinc. The 5rst phase consists of initial distribution outside the vascular system to kidney, liver, and other organs (alpha phase in blood and plasma; t 1/2 of 4 to 5 h). The second phase involves distribution from organs to a slowly exchangeable zinc pool, likely consisting of bone (beta phase in blood and plasma; alpha phase in whole body; t 1/2 of 4 to 20 days). The third phase appears to involve a slow turnover of sequestered zinc (t 1/2 greater than 1 year). Blood sampling or short-term whole-body measurements will underestimate the persistence of zinc in 5sh, thus prolonged sampling and measurement of whole-body concentrations are necessary to characterize the pharmacokinetics of zinc.
Zn was bound to plasma proteins, whereas there was less than 1% binding to red blood cells. Synthesis of the results for channel cat5sh and existing data in other species indicates three phases in the pharmacokinetics of zinc. The 5rst phase consists of initial distribution outside the vascular system to kidney, liver, and other organs (alpha phase in blood and plasma; t 1/2 of 4 to 5 h). The second phase involves distribution from organs to a slowly exchangeable zinc pool, likely consisting of bone (beta phase in blood and plasma; alpha phase in whole body; t 1/2 of 4 to 20 days). The third phase appears to involve a slow turnover of sequestered zinc (t 1/2 greater than 1 year). Blood sampling or short-term whole-body measurements will underestimate the persistence of zinc in 5sh, thus prolonged sampling and measurement of whole-body concentrations are necessary to characterize the pharmacokinetics of zinc.
INTRODUCTION
Zinc is an essential nutrient in "sh and a toxic contaminant of aquatic environments impacted by mining or metal processing operations (Eisler, 1993) . In mammalian species, zinc initially accumulates in the liver, kidney, pancreas, and spleen within the "rst 2 to 24 h of exposure and then is redistributed to bone (Gregus and Klaasen, 1986; Hammond and Beliles, 1980; Rubini et al., 1961; Guillard et al., 1984) . Intravascularly (iv) administered zinc in rats was primarily excreted in the feces (31% of dose) during the "rst 4 days of elimination, and renal and biliary excretion were minor ( 42% of dose) (Gregus and Klaassen, 1986) .
Previous studies have reported either relatively short (a few weeks) or long (several months) half-lives of zinc in both mammals and "sh, depending on the test species and experimental design (Rubini et al., 1961; Shulman et al., 1961; Andermann and Dietz, 1982; Alsop et al., 1999) . For example, whole-body measurements of the half-life of Zn in small "sh range from 13 days in silversides Menidia menidia (Shulman et al., 1961) to greater than 6 months in mosquito"sh Gambusia holbrooki ( formerly, G. a.nis) (Willis and Jones, 1977; Newman and Mitz, 1988) .
The objective of this study was to investigate the pharmacokinetics of iv-administered Zn in the blood, plasma, and whole body of adult channel cat"sh. The pharmacokinetics of iv-administrated zinc has not been previously determined in "sh, but iv dosing has been used in previous pharmacokinetic studies of other chemicals in channel cat"sh (e.g., Barron et al., 1991; Schultz et al., 1996; Schultz and Newman, 1997) . Intravascular administration allows pharmacokinetic determinations in the absence of any confounding e!ects of absorption dynamics and tissue binding at the site of absorption. A nontoxic dose of the radioisotope Zn was administered because of the high concentrations of endogenous zinc in "sh (e.g., 3 to '10 mg/kg; NAS, 1979) . For example, "sh contain 3 to greater than 100 mg Zn/kg (Eisler, 1993) , which may mask the kinetics of low-dose zinc administration (Alsop et al., 1999) . Fish were sampled for nearly 1 year to characterize the persistence of Zn in the channel cat"sh. Also investigated was the binding of Zn to washed red blood cells (RBCs) and to plasma proteins (in the absence of RBCs) because other metals exhibit high binding to these blood components (e.g., Schultz et al., 1996) .
MATERIALS AND METHODS

Fish and Water Quality
Adult channel cat"sh (0.13 to 0.16 kg) of mixed sex were obtained from Orangeburg Aquaculture (Cordova, SC) and maintained in 400-liter recirculating water, "berglass aquarium (LS 700, Frigid Units, Toledo, OH) containing reconstituted hard water (EPA, 1978) and 1 (w/v) NaCl. The loading density of cat"sh in the aquaria was below 5 g/liter Half of the aquarium water was replaced biweekly with aerated, reconstituted water. Chemical characteristics of the freshly prepared water were as follows: total alkalinity 110}120 mg/liter (as CaCO ); hardness 160}180 mg/liter (as CaCO ), and pH 7.9. Temperature and pH in the aquaria were monitored daily, and ranged from 20 to 223 C and 7.7 to 7.9, respectively. Ammonia levels in the aquaria were regularly monitored to ensure that the concentration did not exceed 0.5 mg/liter. Cat"sh were fed a maintenance ration of approximately 2% of their body mass three times per week with soft moist pelleted feed (Rangen, Inc., Buhl, ID). Immediately upon arrival, the cat"sh received a 2-h treatment in a 0.25 mg/liter malachite green (Sigma Chemical) solution and were held a minimum of 30 days before use.
Surgical Procedure
Each cat"sh was "tted with a dorsal aortic cannula using methods described in Schultz et al. (1996) . The cannulated cat"sh were placed in #oating polyethylene cages (Bain Marie containers, 19-liter, 45-cm diameter) which were perforated to allow water exchange. The cages containing cannulated cat"sh were placed in oval 568-liter plastic aquaria "lled with reconstituted hard water and 1 (w/v) NaCl. The end of the cannula was attached to a 1-ml syringe and #oated above the "sh inside the cage. Cat"sh were allowed to recover from surgery for a minimum of 24 h before dosing.
Dosing and Sampling
The ZnCl was obtained from Amersham, Inc. (Arlington Heights, IL). Cat"sh were injected intraaortically with ZnCl (12 g/kg) dissolved in a modi"ed Cortland saline (Schulz and Newman, 1996) . Two protocols were used sequentially to obtain blood samples and whole-animal activity estimates. Initially, serial blood samples were removed via the cannula at 0. 3, 0.7, 1, 1.5, 2, 3, 5, 8, 14, 25, 50, 80 , and 175 h after injection. The cat"sh were not fed during the "rst 2 weeks of sampling. After the blood sample had been removed at 50 h, the whole-animal activity of Zn was quanti"ed by placing the unanesthetized cat"sh for 3 min in a 4-liter Marinelli beaker (GA-MA and Associates, Inc.) containing 1 liter of water. The cat"sh was returned to its cage in the aquarium immediately after counting. At 175 h, the cat"sh was transferred to a constantly aerated, 15-liter solution of MS-222 (150 mg/liter) for 2 min, su$cient time for stage II anesthesia to develop, and was then placed in the Marinelli beaker for counting.
After 175 h, the cannula was removed while the cat"sh were anesthetized, and later blood samples were obtained from the dorsal aorta of the anesthetized cat"sh using a 25-gauge needle and a 1-ml syringe immediately before wholeanimal counting. Such sampling continued for 323 days. Periodically, anesthetized cat"sh were weighed before placement in the Marinelli beaker. After 175 h, cat"sh were fed approximately 2% of their body mass 3 days per week and later reduced to twice weekly, which was su$cient for caged cat"sh to maintain a body weight within 10% of the initial body weight. After resumption of feeding, samples were collected at least 24 h after the last feeding period.
Aliquots of whole blood, plasma, and RBCs were separated from each blood sample, as described in Schultz et al. (1996) . After removal of a blood sample, a fraction was used for whole-blood determination and the remainder centrifuged for 5 min at 2000g to obtain plasma. The RBC pellet was washed twice by resuspension in a 10-fold excess of 0.9% (w/v) NaCl and then centrifuged again; the supernatant was discarded after each wash. The total quantity of blood removed during the initial 196 h was less than 10% of the estimated blood volume (assumed to be 4% of body weight). After 196 h, no more than 3% of the estimated blood volume was removed for each sample.
Gamma Counting and Determination of Zn
The Zn activities of blood products (plasma, blood, RBCs) were determined by counting the samples to a 2 error of 1% in an automated 7.6-cm-wide;8.3-cm-high well-type NaI(Tl) gamma counter (Packard Auto-gamma Model 5530, Packard Instrument Co.). Counts were corrected for radioactive decay to a standard reference date supplied by Amersham, Inc., and converted to values of stable zinc using speci"c activities calculated from the Zn standards. The Zn activities of the whole "sh were estimated using a 7.6-cm-wide;7.6-cm-high well-type NaI(Tl) solid scintillator detector/photomultiplier and multichannel analyzer (Canberra Series 85, Canberra, Meridan, CT). The Marinelli beaker containing the cat"sh was placed on the detector and the gamma emissions were counted for 3 min. Background count rates were determined using a water-"lled Marinelli beaker with the same geometry as used with cat"sh. The net count rates were corrected for radioactive decay to the same reference date used previously for the blood products. At completion of the study, the cat"sh were killed by anesthetic overdose and placed in the Marinelli beaker, and the whole-body count rate was estimated from three separate measurements of 5 min each. Immediately afterward, the cat"sh were homogenized in a Waring blender and aliquots of the homogenate counted in the Packard NaI(Tl) gamma counter. The whole-body count rate was standardized to the Packard gamma counter using the count rate ratio of the whole-body count rate to the count rate for the homogenate. The fraction of the injected dose remaining in the animal (X ) was calculated as the ratio of the adjusted whole-body count rate divided by the activity of the dose which was determined using the Packard gamma counter.
Hematocrit Adjustment
The hematocrit (hct) in nonanesthetized cat"sh was assumed to be 17%. This value is based on unpublished observations of hct values from cannulated cat"sh (Mean $SD: 17.0$5%; n"10) and is similar to values reported by other researchers (e.g., McKim et al., 1994) . The hct of blood samples obtained under anesthesia was measured using heparinized microhematocrit tubes, and Zn concentrations in whole blood and washed RBCs were adjusted to a hct value of 17% by the equation
where C "adjusted blood concentration (ng/ml), C "observed blood concentration (ng/ml), C 0 ! "washed RBC concentration (ng/ml), and C "plasma concentration (ng/ml). The washed RBC concentration was calculated by the equation
where X 0 ! "amount of Zn in the washed RBCs (ng), and blood volume was the fraction of the blood sample used to obtain the washed RBCs.
Plasma Binding
Binding of Zn to plasma proteins was determined by centrifugation (1500g) of plasma samples through Centrifree (Amicon, Inc., Beverly, MA) "ltration tubes (30,000-Da cuto! ). The percentage bound was calculated from the ratio of radioactivity in the plasma "ltrate and the radioactivity in the original plasma sample: % bound"[1!(dpm in "ltrate/dpm in sample)];100.
Pharmacokinetics
The pharmacokinetics of Zn were evaluated by modeling mean concentrations in blood (n"1 to 6), plasma (n"2 to 6), and whole body (n"4) using WinNonlin software (Statistical Consultants, Inc., Apex, NC). Multicompartmental models with clearance constants as parameters were used in "tting the data (Barron et al., 1990) . The most appropriate compartmental model for each data set was determined from the uncertainty of the estimated parameters [i.e., coe$cient of variation for total body clearance (Cl ), volume of distribution of the central compartment (< ), and the sum of all compartment volumes (< ), mean residence time (MRT), and terminal elimination half-life (t )], and the absence of systematic bias in plots of observed and model predicted zinc concentrations.
RESULTS
Blood and Plasma Pharmacokinetics
Mean blood concentrations of Zn exhibited a biexponential decline from 318 to 11 ng/ml during the "rst 37 days following iv administration (Fig. 1) . Mean plasma concentrations of Zn also exhibited a biexponential decline, decreasing from 340 (0.01 days) to 8 (37 days) ng/ml (Fig. 2) . Mean concentrations of Zn in red blood cells were very low and relatively constant during the "rst 37 days, ranging from 4.5 to 15 ng/ml (Fig. 2) . Concentrations of Zn in a single "sh sampled for 323 days declined to nearly nondetectable levels (blood: 2.5 ng/ml; plasma: 2.1 ng/ml; RBCs: 0.5 ng/ml) (data not provided). These samples were counted to a 2-sigma level of con"dence (98%) to ensure the accuracy of the low-level measurements. The Zn in blood was greater than 99% bound to plasma proteins (data not shown). A two-compartment model best described the Zn pharmacokinetics in the blood and plasma of channel cat-"sh during the "rst 37 days following iv administration. The elimination from the vascular system (Cl ), extent of tissue distribution (< , < ), and persistence in the vascular system (MRT, t ) of Zn was similar for both plasma and blood determinations ( Table 1 ). The half-life of the "rst distributive (alpha) phase of Zn in blood and plasma was approximately 4.5 h. Preliminary modeling and sample data for a single cat"sh indicated that elimination from the vascular system was minimal after 50 h and that blood and plasma concentrations declined to a nearly constant value of 2 to 3 ng/ml.
Whole-Body Pharmacokinetics
Mean concentrations of Zn in whole-body samples of channel cat"sh exhibited a biexponential decline from 12.3 to 6.6 g/kg during a 323 day elimination period following iv administration (Fig. 3) . Cat"sh maintained '90% of their surgery weight during the nearly year-long study. A two-compartment model also best described the pharmacokinetics of Zn in the whole-body of cat"sh. However, in contrast to blood and plasma, whole-body concentrations of Zn exhibited a more prolonged distribution period (alpha phase t of 4.3 days) and extremely slow elimination (t of 1.5 years). Whole-body pharmacokinetics also exhibited a relatively larger volume of distribution than Zn in blood and plasma (Table 1 ). Figure 3 shows that the percentage of the iv dose eliminated from channel cat"sh was 20% after 37 days, and 48% after 323 days.
DISCUSSION
A two-compartment model described the pharmacokinetics of Zn in plasma and blood during the "rst 37 days following iv administration, but was unable to describe the long-term disposition of Zn in channel cat"sh. Preliminary modeling and data for a single "sh indicated that elimination from the vascular system was minimal after 50 h and that blood concentrations declined to a nearly constant value of 2 to 3 ng/ml. Whole-body counting revealed that approximately half of the Zn dose was sequestered in a slowly exchangeable pool with a half-life of 1.5 years. Blood and plasma levels of Zn exhibited a 95% decline in the "rst 20 days due to distribution outside of the vascular system, rather than elimination. The majority of Zn loss from the vascular system occurred within the "rst 24 h. For example, plasma concentrations declined 80% within 24 h of iv administration. In contrast, approximately 100% of the dose was retained in the whole body of channel cat"sh for the "rst 48 h and greater than 80% of the dose was still in the "sh 20 days following iv administration.
Previous studies have reported either relatively short (a few weeks) or long (several months) half-lives of zinc in both mammals and "sh, depending on the test species and ZINC KINETICS IN CATFISH et al. (1984) experimental design (Rubini et al., 1961; Shulman et al., 1961; Andermann and Dietz, 1982; Alsop et al., 1999) (Table  2) . For example, whole-body measurements of the half-life of Zn in "sh range from 13 days to greater than 6 months (Shulman et al., 1961; Willis and Jones, 1977; Newman and Mitz, 1988) . In agreement with the current results, Nakatani (1966) observed a rapid loss of zinc in blood, and very slow loss of whole-body levels (e.g., t of 5 months). Alsop et al. (1999) reported fast and slow turnover pools of zinc in rainbow trout blood, but only a slow turnover pool was evident in the whole body (turnover rate of 216 g/kg per day). Mosquito"sh at steady state with zinc exhibited three reservoirs of zinc containing 9, 4, and 91% of zinc, and the terminal elimination half-life was 235 days (Willis and Jones, 1977) . The Zn in the blood of mice and rats was less than 0.01% of whole-body radioactivity, indicating rapid extravascular distribution (Rubini et al., 1961) . Total-body turnover of Zn in mice was initially rapid (approximate half-life of 6 days) followed by a slower decline ('30 day half-life) (Cotzias et al., 1962) . Elimination of whole-body Zn from mice was accelerated by administration of a metabolic load of stable zinc, whereas administration of metabolic loads of cadmium, copper, or gallium had no e!ect (Cotzias et al., 1962) .
The model-estimated volume of the central compartment (< ) determined in channel cat"sh blood (44 ml/kg) was only slightly larger than the vascular volume in "sh (Olson, 1992) . The steady-state volume of distribution (< ) determined from intravascular kinetics was 25% of body weight, and thus may comprise tissues that are well perfused with blood such as the visceral organs and red muscle (Schultz et al., 1999) . Bone may represent the slow turnover pool in both "sh and mammals. In rats, injected Zn was "rst deposited in the pancreas, liver, and spleen, then a large proportion was transferred to bone (Rubini et al., 1961) . Six months after zinc administration in rainbow trout (Oncorhynchus mykiss), bone had the highest zinc concentration of any tissue and the slowest elimination (Nakatani, 1966) . Rapidly growing juvenile chinook salmon (Oncorhynchus tshawytscha) accumulated Zn from water and retained nearly all of it for 63 days after transfer to uncontaminated media; most of the zinc was translocated to the vertebral column, head, and visceral mass (Joyner and Eisler, 1961) . Juvenile channel cat"sh fed 200 mg zinc for 12 weeks had elevated bone zinc levels (359 mg/kg dw) relative to control "sh (254 mg/kg dw) (Gatlin et al., 1989) . Bently (1991) also reported high concentrations of zinc in bone of channel cat"sh (59 mg/kg ww), suggesting that 30 to 40% of zinc residues were in bone (calculated using a relative bone weight of 18% of body weight in channel cat"sh; Schultz et al., 1999) . The outer surface of the bone seems to be an ion-exchange medium capable of sequestering large quantities of metal ions through the process of overlayering by growing bone.
The pharmacokinetics of Zn in blood were nearly identical to plasma because of minimal binding to RBCs. Greater than 99% of the circulating Zn was bound to plasma proteins, whereas there was less than 1% binding to red blood cells. Bently (1991) previously reported higha$nity binding of zinc to speci"c plasma proteins in channel cat"sh. Concentrations of Zn were near detection limits (0.5 ng/ml) but appeared to represent a low, relatively constant, level of binding to RBCs (i.e., 1 to 15 ng/ml). In contrast, several other metals in channel cat-"sh exhibit substantially higher binding to RBCs (Schultz et al., 1996, Schultz and Newman, 1997) . Current results with zinc are in contrast to studies in rodents that have suggested that zinc concentrates in the membrane of the RBC (Bettger et al., 1987) .
CONCLUSION
The results of this study con"rm the long biological half-life of zinc in "sh, and suggest that previous reports of a limited persistence of metals in "sh should be interpreted relative to the experimental design and measurement methods used. Synthesis of the results for channel cat"sh and existing data in other species indicates three phases in the pharmacokinetics of zinc. The "rst phase consists of initial distribution outside the vascular system to organs such as kidney, liver, and spleen (alpha phase in blood and plasma; t of 4 to 5 h). The second phase involves distribution from organs to a slowly exchangeable zinc pool, likely consisting of bone (beta phase in blood and plasma; alpha phase in whole body; t of 4 to 20 days). The third phase appears to involve a slow turnover of sequestered zinc (t greater than 1 year). In agreement, three phases of zinc disposition are evident from whole-body measurements in mosquito"sh (Willis and Jones, 1977) and plasma measurements in dogs (Rubini et al., 1961) . Blood sampling or short-term whole-body measurements will underestimate the persistence of zinc in "sh, thus prolonged sampling and measurement of whole body concentrations are necessary to characterize the pharmacokinetics of zinc.
